EFFORT Extension Study

A 3-year, Open-label, Multi-center Extension Trial of Telbivudine Therapy for Patients Previously Treated in EFFORT Clinical Trial

• The purpose of this study is to to prove that the long-term efficacy of strategy of treatment adjustment at W24 according to virological response based on ROADMAP concept is better than standard of care strategy.
• To evaluate the off-treatment durability of HBeAg seroconversion in patients who discontinued treatment due to sustained HBeAg seroconversion and HBV DNA<300copies/ml with over 12 months consolidation treatment

Inclusion Criteria:

• Treated with telbivudine or combined with adefovir in EFFORT study
• Patients are willing to participate in the extension study
• Patients provide information consent form

Exclusion Criteria:

• Adjustment of poor compliance by investigators